Patient description: Patient A is a 30-year-old male who was admitted to the hospital after 10 days of cough, profuse nocturnal sweating and loss of appetite. He had traveled to India 1 months ago and has not any positive history of TB vaccination. He is a previously healthy man, working as an engineer in a high tech company. He doesn't smoke o use any illicit drugs. He was febrile (38 c) with heart rate of 115 b/min, respiratory rate of 22, BP of 125/75 mmHg and O2 sat of 97%. Chest X-ray showed infiltrate in the middle of left lung with diameter of 1.8 cm with signs of cavitation. The sputum smear revealed positive sputum culture for Mycobacterium tuberculosis which are sensitive of the first-line TB drugs (isoniazid, streptomycin, rifampicin and ethambutol). Lab study is reported bellow: Hgb: 13 g/dl WBC: 14000 /mm3 Plt: 300000 /ml AST: 13 U/L ALT: 15 U/L Alk P: 53 U/L Bill total: 0.6 mg/dl Na: 137 mEq/l K: 4 mEq/l Creatinine: 0.5 mg/dl BUN: 10 mg/dl ESR: 120 mm/hr

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cystic Fibrosis Confirmed diagnosis of Cystic Fibrosis based on the following positive sweat chloride 60 mEq/liter (by pilocarpine iontophoresis); and/or a genotype with two identifiable mutations consistent with CF 2. Presence of Pseudomonas aeruginosa, Staphylococcus aureus or Stenotrophomonas maltophilia in the screening sputum culture. 3. Chronic microbial lung colonization (≥6 months) with presence of Pseudomonas aeruginosa, Staphylococcus aureus or Stenotrophomonas maltophilia in at least two (2) sputum cultures in the past year (the screening culture can count as one of the two positive cultures). 4. Ongoing chronic inhaled antibiotic therapy for at least 3 months prior to (screening or baseline). • For subjects on cycled therapy, at least 2 cycles of drug need to have been completed prior to baseline. 5. Willing to be off of inhaled antibiotic therapy from Day 1 to Day 15 6. Male or female subjects ≥18 years 7. FEV1 <85% and >35% at screening and baseline 8. SaO2 >90% on room air at screening and baseline 9. Clinically stable with no significant changes in health status within 14 days prior to Baseline 10. Written Informed Consent and HIPAA authorization 11. Non-smoker for at least 6 months prior to screening and agrees not to smoke during the study 12. Chest x-ray within the last six (6) months. If none, a chest x-ray is required before randomization. 13. Willing and able to comply with the treatment schedule and procedures  Initiation of any new chronic therapy (e.g., ibuprofen, Pulmozyme®, hypertonic saline, azithromycin, TOBI®, Cayston®) within 4 weeks prior to screening. 2. Use of antibiotics [oral, intravenous (iv), and/or inhaled] for acute respiratory symptoms within 2 weeks prior to baseline. 3. Significant hemoptysis within 30 days prior to screening (≥5 mL of blood in one coughing episode or >30 mL of blood in a 24 hour period) 4. History of colonization with nontuberculosis mycobacterium in sputum culture. The investigator can be guided by the following suggested for a subject to be considered free of colonization Two respiratory tract cultures negative for NTM in the last year, with no subsequent positive cultures; and these 2 respiratory cultures must be separated by at least 3 months; and one of these two cultures has to have been obtained within the last 6 months 5. Cardiac (left heart) insufficiency (defined as LVEF <35%) at screening 6. Use of a nitric oxide donor agent such as nitroglycerin or drugs known to increase methemoglobin such as lidocaine, prilocaine, benzocaine or dapsone at screening 7. Any of the following abnormal lab values at Screening Hemoglobin < 10 g/dl Methemoglobn >3% Platelet count <100,000/mm3 Prothrombin time international ratio (INR) > 1.5 Abnormal liver function defined as any two of the following ALT >3 x ULN